Drug-induced acute interstitial nephritis (AIN) is an established cause of acute kidney injury (AKI). Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequent offending drugs \[[@R1]\]. Only a few vitamin K antagonist-induced AIN cases have been reported. Some publications describe AIN associated with fluindione (Previscan®), an anticoagulant of the antivitamin K family, derived from indanedione, exclusively marketed in France. We present an additional case of AIN secondary to fluindione and review the available literature.

A 70-year-old woman was hospitalized for AKI. Her treatment list included amlodipine and atenolol. In December 2007, the serum creatinine (SCr) level was 70 μmol/L and an asymptomatic atrial fibrillation was detected. Fluindione was hence initiated. SCr rose to 220 μmol/L (04/08). On admission, her SCr level had reached 3.4 mg/dL and fluindione was stopped. Blood pressure was 110/ 80 mmHg, and neither cutaneous rash nor peripheral lymphadenopathy was found. Laboratory tests showed SCr 299.2 μmol/L, proteinuria 2 g/24 h (1 g albumin and low-molecular-weight proteins, each) and negative urine sediment. A renal ultrasound revealed reduced-sized (10 cm) kidneys without obstructive uropathy. Immunological analyses were negative. A transjugular renal biopsy was performed. The renal biopsy included 11 glomeruli; 5 were sclerotic and 6 were normal. A diffuse infiltrate of lymphocytes, eosinophils and monocytes was found in the interstitium associated with severe tubulitis (Figure [1](#F1){ref-type="fig"}). Immunostains demonstrated CD3-positive lymphoid cells in the interstitium (Figure [2](#F2){ref-type="fig"}) compared to CD20 immunohistochemical staining (Figure [3](#F3){ref-type="fig"}). Immunofluorescence was negative. Electron microscopy was not performed. The diagnosis of fluindione-induced AIN (FI-AIN) was made. Despite withdrawal of the offending agent replaced by acenocoumarol, and oral corticosteroid therapy (1 mg/kg/day), renal function did not return to baseline values after 1 month (SCr, 259.6 μmol/L) but improved to 199.8 μmol/L 6 months later.

![Renal biopsy specimen showing expansion of the renal interstitium by large lymphocyte inflammatory cell aggregates and severe tubulitis. Masson\'s trichrome stain; original magnification ×40.](sfn171fig1){#F1}

![Immunophenotyping analysis showing positive CD3 + T cells. Original magnification ×400.](sfn171fig2){#F2}

![Immunophenotyping analysis showing few CD20 + lymphocytes. Original magnification ×400.](sfn171fig3){#F3}

About 15% of the renal biopsies performed on patients with AKI demonstrate drug-induced AIN as the cause of the renal insufficiency. Only 13% of these patients showed the classic triad of rash, fever and eosinophilia. Discontinuation of the offending drug remains the first therapeutic step. Nevertheless, a considerable part of the affected patients may develop ESRD (23.4%). An important clinical prognostic factor is the average duration of the renal dysfunction; a cut-off point of 2--3 weeks seems relatively determining \[[@R1]--[@R3]\].

Few cases of vitamin K antagonist-induced AIN have been reported with warfarin, phenindione and fluindione \[[@R4]\]. Hypersensitivity reactions occur in 0.2--2% of cases \[[@R5]\]. Review of the literature revealed 16 biopsy-proven FI-AIN \[[@R5]\], including this case (Table [1](#T1){ref-type="table"}). AKI appeared 7.5 ± 6.9 weeks (range 2--20) after introducing the offending drug. The average baseline SCr was (102.08 ± 35.2; range 62.5--149.6 μmol/L) obtained 7.5 ± 4.6 (range 0.5--16) months before the onset of FI-AIN. Fifty percent of patients showed proteinuria (0.3--19.7 g/24 h) associated with microscopic haematuria (12.5%) and leukocyturia (12.5%). The highest SCr reached between 135.52 and 824.56 μmol/L with a mean of 425.04 ± 243.76 μmol/L. Two patients (12.5%) required several sessions of haemodialysis \[[@R9]\]. Thirty-one percent (5/16) presented the classical triad of drug-induced AIN: fever, maculopapular rash and eosinophilia. The renal biopsy was obtained in 14 out of the 16 patients. In all cases, a diffuse inflammatory infiltrate composed of lymphocytes, eosinophils, monocytes and plasma cells invading the interstitial compartment was observed. Fluindione was withdrawn in all patients. Eleven patients (68.75%) were treated with steroids. Steroid doses and the duration of treatment were not uniform. The most common scheme consisted of oral prednisone (0.5--1 mg/kg/day) tapering off over 8--12 weeks. Intravenous pulses of methylprednisolone (250--500 mg daily for 3 days) were occasionally used. In 3 out of these 11 steroid-treated patients (27.3%), SCr never reached baseline values. The five patients who did not receive steroids had a complete recovery of baseline renal function 10 days to 3 weeks after withdrawal of the offending drug. However, the largest study to date by González *et al*. demonstrated the beneficial effects of steroids for the treatment of drug-induced AIN, especially when initiated soon after withdrawal of the offending agent \[[@R1]\].

###### 

Characteristics of patients with fluindione-induced acute interstitial nephritis

  Authors                         Parameters                                                                                                                                                                                                                                                   
  ------------------------------- ------------ ------------ --------------------- --------------------- --------------------- ------------------------------------------------------------------ ---------- -------------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------
  Gilson *et al*. \[[@R6]\]       M            75           MI                    Phlebitis             5 months              Non-oliguric ARF (from 62.5 to 135.52 μmol/L)                      NA         Acute IN                         Drug withdrawal, steroid                          Renal function did not reach baseline values at 6 months
  Sparsa *et al*. \[[@R5]\]       M            84           MI stroke             Atrial fibrillation   8 weeks               Non-oliguric ARF (from 88 to 374 μmol/L);                          Positive   Acute IN                         Drug withdrawal, steroid                          Complete recovery of baseline renal function after 5 weeks
                                                                                                                              fever, bronchial spasms, eosinophilia                                                                                                                            
                                  M            83           MI                    Phlebitis             4 weeks               Non-oliguric ARF (147.84 μmol/L), proteinuria 0.43 g/day           Positive   NA                               Drug withdrawal                                   Complete recovery of baseline renal function after 3 weeks
  Thurot *et al*. \[[@R7]\]       M            68           Asthma                Atrial fibrillation   3 weeks               Non-oliguric ARF (88--136.4 μmol/L), haematuria, leukocyturia,     Positive   NA                               Drug withdrawal                                   Positive reintroduction test; complete recovery of baseline renal function after 10 days
                                                                                                                              proteinuria 19.7 g/day, fever, rash, eosinophilia                                                                                                                
  Coin *et al*.^\*^               M            79           Heart failure         Atrial fibrillation   2 months              Non-oliguric ARF                                                   Positive   Acute IN                         NA                                                NA
  Raynaud *et al*.^\*^            3 M          46; 74; 70   CRF                   Atrial fibrillation   3 weeks to 2 months   Non-oliguric ARF, fever, erythroderma, eosinophilia                NA         Acute IN                         Drug withdrawal, steroid dialysis (one patient)   Positive reintroduction test; complete recovery of baseline renal function after 10 days
  Grimaldi *et al*. \[[@R8]\]     M            73           CRF                   Atrial fibrillation   5 weeks               Non-oliguric ARF (106.5--352.9 μmol/L), proteinuria                NA         Acute IN, tubulitis              Drug withdrawal                                   Complete recovery of baseline renal function after 2 weeks
                                  W            80           CRF                   Phlebitis             4 months              Non-oliguric ARF (99.44--374 μmol/L), proteinuria 0.5 g/day        NA         Acute IN, tubulitis              Drug withdrawal                                   Death related to pulmonary embolism
  Belmonaz *et al*. \[[@R9]\]     M            70           NA                    Phlebitis             3 weeks               Proteinuria 0.3 g/day, fever, eosinophilia                         NA         Acute IN                         Drug withdrawal, steroid (IV pulses then oral)    Complete recovery of baseline renal function (SCr 1.1 mg/dL) after 2 weeks
                                                                                                                              proteinuria 0.3 g/day, fever, eosinophilia                                                                                                                       
  Boulon *et al*. \[[@R10]\]      M            70           Diabete, HT, CRF      Phlebitis             3 weeks               Non-oliguric ARF (149.6--759.44 μmol/L), proteinuria 3 g/24 h      NA         Acute IN, glomerular sclerosis   Drug withdrawal, steroid, dialysis                Renal function did not reach baseline values at 1 month (SCr 2.84 mg/dL)
  Beauchamp *et al*. \[[@R11]\]   M            78           MI, diabetes          Atrial fibrillation   1 month               Non-oliguric ARF (735.7 μmol/L)                                    NA         Acute IN                         Drug withdrawal, steroid                          Positive reintroduction test; complete recovery of baseline renal function after 6 months
                                  M            72           BP cancer, diabetes   Atrial fibrillation   1 month               Non-oliguric ARF (86.24--824.56 μmol/day), proteinuria 0.4 g/day   NA         Acute IN                         Drug withdrawal, steroid                          Partial recovery of baseline renal function
                                  M            55           IgA nephropathy       AVR                   15 days               Non-oliguric ARF (170.72--559.7 μmol/L)                            NA         Acute IN, tubulitis              Drug withdrawal, steroid                          Complete recovery of baseline renal function after 6 months
  This case                       W            70           Hypertension          Atrial fibrillation   5 months              Non-oliguric ARF (69.52--299.2 μmol/day), proteinuria 2 g/day      NA         Acute IN, tubulitis              Drug withdrawal, steroid                          Ongoing

M, men; W, women; MI, myocardial infarction; ARF, acute renal failure; CRF, chronic renal failure; IN, interstitial nephritis; NA, not available; AVR, aortic valvular replacement; HT, hypertension.

^\*^Not published.

Teaching point {#S1}
==============

Fluindione must be considered amongst drugs that induce AIN.
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